Advances of Patient-Derived Organoids in Personalized Radiotherapy

Wang, Yuenan1; Li, Ye2; Sheng, Zonghai2; Deng, Weiwei3; Yuan, Hongyan3; Wang, Shubin4; Liu, Yajie1

2022-04-29

10.3389/fonc.2022.888416

Frontiers in Oncology   影响因子和分区

2234-943X

Patient-derived organoids (PDO), based on the advanced three-dimensional (3D) culture technology, can provide more relevant physiological and pathological cancer models, which is especially beneficial for developing and optimizing cancer therapeutic strategies. Radiotherapy (RT) is a cornerstone of curative and palliative cancer treatment, which can be performed alone or integrated with surgery, chemotherapy, immunotherapy, or targeted therapy in clinical care. Among all cancer therapies, RT has great local control, safety and effectiveness, and is also cost-effective per life-year gained for patients. It has been reported that combing RT with chemotherapy or immunotherapy or radiosensitizer drugs may enhance treatment efficacy at faster rates and lower cost. However, very few FDA-approved combinations of RT with drugs or radiosensitizers exist due to the lack of accurate and relevant preclinical models. Meanwhile, radiation dose escalation may increase treatment efficacy and induce more toxicity of normal tissue as well, which has been studied by conducting various clinical trials, very expensive and time-consuming, often burdensome on patients and sometimes with controversial results. The surged PDO technology may help with the preclinical test of RT combination and radiation dose escalation to promote precision radiation oncology, where PDO can recapitulate individual patient' tumor heterogeneity, retain characteristics of the original tumor, and predict treatment response. This review aims to introduce recent advances in the PDO technology and personalized radiotherapy, highlight the strengths and weaknesses of the PDO cancer models, and finally examine the existing RT-related PDO trials or applications to harness personalized and precision radiotherapy.

patient-derived organoid (PDO) patient-derived xenograft (PDX) radiosensitizer personalized medicine radiotherapy

SCI

英语

其他

CAS Key Laboratory of Health Informatics, Shenzhen Institute of Advanced Technology[2011DP173015] ; Shenzhen Technology andInnovation Program[JCYJ20210324110210029] ; Research Foundation of Peking University Shenzhen Hospital[JCYJ2020015]

Oncology

Oncology

WOS:000796715300001

FRONTIERS MEDIA SA

Web of Science

1.Peking Univ, Dept Radiat Oncol, Shenzhen Hosp, Shenzhen, Peoples R China
2.Chinese Acad Sci, Shenzhen Inst Adv Technol, Inst Biomed & Hlth Engn, Paul C Lauterbur Res Ctr Biomed Imaging, Shenzhen, Peoples R China
3.Southern Univ Sci & Technol, Dept Mech & Aerosp Engn, Shenzhen, Peoples R China
4.Peking Univ, Dept Med Oncol, Shenzhen Hosp, Shenzhen, Peoples R China

Wang, Yuenan,Li, Ye,Sheng, Zonghai,et al. Advances of Patient-Derived Organoids in Personalized Radiotherapy[J]. Frontiers in Oncology,2022,12.

Wang, Yuenan.,Li, Ye.,Sheng, Zonghai.,Deng, Weiwei.,Yuan, Hongyan.,...&Liu, Yajie.(2022).Advances of Patient-Derived Organoids in Personalized Radiotherapy.Frontiers in Oncology,12.

Wang, Yuenan,et al."Advances of Patient-Derived Organoids in Personalized Radiotherapy".Frontiers in Oncology 12(2022).